New survey findings from the American Society of Health-System Pharmacists (ASHP) shows that roughly 99% of health-system pharmacists said they are experiencing drug shortages. Nearly one-third of the respondents said the current shortages are “critically impactful,” causing facilities to delay, ration, or cancel procedures or treatments.

New findings from the SELECT trial indicate that semaglutide (Wegovy—Novo Nordisk) reduces the risk of major heart complications—heart attacks, strokes, and CV deaths—by 20%. The 5-year randomized trial of approximately 17,500 patients is the first to demonstrate that an obesity drug can have long-term CV benefits.

A new study in JAMA Network Open found that as drug overdose deaths have reached unprecedented levels in the United States, evidence-based treatments for substance use are severely underused.

According to the American Heart Association (AHA), significant disparities for stroke risk factors exist between Black adults and non-Black adults who have had a stroke.

In July, FDA approved nirsevimab-alip (Beyfortus—Sanofi/AstraZeneca). A few weeks later, on August 3, 2023, CDC’s ACIP voted unanimously to recommend the broad use of the new drug to infants and high-risk children for protection against respiratory syncytial virus (RSV).